Cara Therapeutics to Present at Upcoming Investor Conferences

Rhea-AI Summary

Cara Therapeutics, Inc. (Nasdaq: CARA) announced investor conference presentations by its Executive Leadership Team. Key dates include the Stifel Healthcare Conference on November 15, the Jefferies London Healthcare Conference on November 16, the Evercore ISI Healthcare Conference on November 29, and the Piper Sandler Healthcare Conference on December 1, 2022. Webcasts will be available in the 'Events & Presentations' section of the Cara website, with recordings accessible for 30 days. The company focuses on innovative pruritus treatments, including the FDA-approved KORSUVA®.

STAMFORD, Conn., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced that members of its Executive Leadership Team will present at the following investor conferences:

Stifel Healthcare Conference
Tuesday, November 15, 2022, at 10:55 a.m. ET

Jefferies London Healthcare Conference
Wednesday, November 16, 2022, at 10 a.m. ET (3 p.m. GMT)

Evercore ISI Healthcare Conference (virtual)
Tuesday, November 29, 2022, at 8:25 a.m. ET

Piper Sandler Healthcare Conference
Thursday, December 1, 2022, at 8 a.m. ET

Webcasts of the presentations can be accessed under "Events & Presentations" in the News & Investors section of the Company's website at www.CaraTherapeutics.com. Archived webcast recordings will be available on the Cara website for approximately 30 days.

About Cara Therapeutics

Cara Therapeutics is a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus. The Company’s novel KORSUVA^® (difelikefalin) injection is the first and only FDA-approved treatment for moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis. The Company is developing an oral formulation of difelikefalin and has initiated Phase 3 programs for the treatment of pruritus in patients with non-dialysis dependent advanced chronic kidney disease and atopic dermatitis. The Company has completed a Phase 2 proof-of-concept trial of oral difelikefalin for the treatment of moderate-to-severe pruritus in patients with notalgia paresthetica. A Phase 2 proof-of-concept trial in primary biliary cholangitis patients with moderate-to-severe pruritus is ongoing. For more information, visit www.CaraTherapeutics.com and follow the company on Twitter, LinkedIn and Instagram.

MEDIA CONTACT:
Annie Spinetta
6 Degrees
973-768-2170
aspinetta@6degreespr.com

INVESTOR CONTACT:
Iris Francesconi, Ph.D.
Cara Therapeutics
203-406-3700
investor@caratherapeutics.com

 

FAQ

When is Cara Therapeutics presenting at the Stifel Healthcare Conference?

Cara Therapeutics will present at the Stifel Healthcare Conference on November 15, 2022, at 10:55 a.m. ET.

What is the focus of the presentations by Cara Therapeutics?

The presentations by Cara Therapeutics will focus on their innovative treatments for pruritus and recent developments in their product pipeline.

Where can I access the webcasts of Cara Therapeutics' presentations?

Webcasts of Cara Therapeutics' presentations can be accessed under 'Events & Presentations' on their official website.

What is KORSUVA® and its significance for Cara Therapeutics?

KORSUVA® is the first FDA-approved treatment for moderate-to-severe pruritus associated with chronic kidney disease, marking a key innovation for Cara Therapeutics.

What other events is Cara Therapeutics participating in after November 16, 2022?

After November 16, Cara Therapeutics will participate in the Evercore ISI Healthcare Conference on November 29 and the Piper Sandler Healthcare Conference on December 1, 2022.